Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSQPCT)

Drug Name

ALXN1850 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hypophosphatasia	5C64.3	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Alkaline phosphatase tissue-nonspecific (ALPL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Asfotase alfa	DMM4FXA	Genetic disease	8E02	Approved	[3]
Levamisole	DM5EN79	Parasitic infection	1D0Y-1G2Z	Approved	[4]
DS-1211	DMY3T0L	Pseudoxanthoma elasticum	EC40	Phase 2	[5]
ALXN1910	DMDXTAE	Discovery agent	N.A.	Phase 1	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alkaline phosphatase tissue-nonspecific (ALPL)	TTMR5UV	PPBT_HUMAN	Replacement	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04980248) A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Alexion
3	Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012 Mar 8;366(10):904-13.
4	Characterization of rat heart alkaline phosphatase isoenzymes and modulation of activity. Braz J Med Biol Res. 2008 Jul;41(7):600-9.
5	In Vitro and In Vivo Pharmacological Profiles of DS-1211, a Novel Potent, Selective, and Orally Bioavailable Tissue-Nonspecific Alkaline Phosphatase Inhibitor. J Bone Miner Res. 2022 Oct;37(10):2033-2043.